Swarandeep Singh

About

I am currently working as a Research Associate at the All India Institute of Medical Sciences (AIIMS), New Delhi, India. My primary expertise is in the design and development of HIV-1 vaccines, with a focus on monoclonal antibody discovery. I have specialized experience in designing and testing nanoparticle-based HIV-1 vaccines in preclinical animal models. My research aims to advance the understanding and effectiveness of vaccines against HIV-1, leveraging innovative approaches in vaccine delivery systems and immune response enhancement.

Employment

• All-India Institute of Medical Sciences Research Associate
  2023 - Present
• AMC Visiting Fellow
  2023 - 2023
• All India Institute of Medical Sciences Ph.D. Scholar
  2018 - 2023

Education

• All-India Institute of Medical Sciences Ph.D.
  2018 - 2023

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• Cisplatin Induced Ototoxicity in Patients with Head and Neck Malignancies: A Clinical Study
  Indian Journal of Otolaryngology and Head & Neck Surgery 2026 DOI: 10.1007/s12070-026-06837-6
  +Save
• Human Antibody Isotypes, Subclasses, Allotypes and Fc Biology: Clinical Implications in Infectious Diseases, Autoimmunity, and Cancer
  Pharmaceuticals 2026 DOI: 10.3390/ph19081290
  +Save
• Viral Vaccine Adjuvant Strategies for Shaping Durable Immunity Across the Human Lifespan
  Vaccines 2026 DOI: 10.3390/vaccines14060508
  +Save
• Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response
  Journal of Virology 2026 DOI: 10.1128/jvi.02202-25
  +Save
• Immunogenicity and Structure of stabilized HIV-1 Clade-C Env from pediatric Elite-neutralizer complexed with autologous bNAb
  2025 DOI: 10.1101/2025.04.26.649701
  +Save
• The Design and Immunogenicity of an HIV-1 Clade C Pediatric Envelope Glycoprotein Stabilized by Multiple Platforms
  Vaccines 2025 DOI: 10.3390/vaccines13020110
  +Save
• An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1
  ACS Omega 2023 DOI: 10.1021/acsomega.2c07933
  +Save
• Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody
  iScience 2023 DOI: 10.1016/j.isci.2023.107579
  +Save
• The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41
  International Immunopharmacology 2021 DOI: 10.1016/j.intimp.2021.108187
  +Save
• Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus
  International Immunopharmacology 2021 DOI: 10.1016/j.intimp.2021.108020
  +Save